Suppr超能文献

[CACNA1C基因多态性对钙通道阻滞剂降压疗效的影响]

[Impact of CACNA1C polymorphisms on antihypertensive efficacy of calcium channel blocker].

作者信息

Sun Qian, Li Qing-xian, Song Xi-fa, Zheng Song-gui, Yan Feng, Chen Peng, Tang Ji-fei, Niu Yu-xin, Bao Qi-yu, Zhang Guo-qiang, Hu Yun-liang

机构信息

Department of Clinical Laboratory, Wenzhou Medical College, Wenzhou, China.

出版信息

Zhonghua Xin Xue Guan Bing Za Zhi. 2012 Jan;40(1):3-7.

Abstract

OBJECTIVE

To explore the relationship between genetic polymorphisms of CACNA1C that encoded the a1c subunit of the L-type calcium channel and the efficacy of calcium channel blocker (CCB, Nifedipine extended release tablet/20 mg/d) in essential hypertension (EH) patients of Han Chinese in Wenzhou.

METHODS

For the enrolled 103 EH patients, Multiplex Polymerase Chain Reaction (Multi-PCR) and matrix assisted laser desorption ionization time of flight MS (MLDI-TOF MS) were performed to detect their genotypes (rs216008, rs1051375, rs2299661, rs10848683, rs215976), blood pressure (BP) after CCB monotherapy was compared among patients with different genotypes.

RESULTS

(1) Blood pressure was significantly reduced in all patients post CCB (P < 0.05 vs. pre-CCB). (2) Diastolic blood pressure reduction was more significant in subjects with rs2299661 C/C genotype (wild genotype) than in subjects with rs2299661C/G and rs2299661G/G genotype (mutational genotype) [(12.46 ± 7.91) mm Hg (1 mm Hg = 0.133 kPa) vs. (7.22 ± 8.01) mm Hg and (5.93 ± 9.77) mm Hg, P < 0.05]. (3) Systolic blood pressure reduction was more significant in subjects with rs216008 C/C genotype (wild genotype) than in subjects with rs216008 C/T genotype (mutational genotype) [(20.60 ± 12.35) mm Hg vs. (13.62 ± 10.21) mm Hg, P < 0.05]. (4) Blood pressure reduction was similar between subjects with genotype of rs1051375, rs10848683 and rs215976.

CONCLUSION

EH patients with wild genotype of rs2299661 and rs216008 in CACNA1C are more likely to be responders of CCB monotherapy.

摘要

目的

探讨编码L型钙通道α1c亚基的CACNA1C基因多态性与温州汉族原发性高血压(EH)患者使用钙通道阻滞剂(CCB,硝苯地平缓释片/20mg/d)疗效之间的关系。

方法

对纳入的103例EH患者,采用多重聚合酶链反应(Multi-PCR)和基质辅助激光解吸电离飞行时间质谱(MLDI-TOF MS)检测其基因型(rs216008、rs1051375、rs2299661、rs10848683、rs215976),比较不同基因型患者CCB单药治疗后的血压(BP)。

结果

(1)所有患者CCB治疗后血压均显著降低(与CCB治疗前相比,P<0.05)。(2)rs2299661 C/C基因型(野生型)患者的舒张压降低幅度比rs2299661 C/G和rs2299661 G/G基因型(突变型)患者更显著[(12.46±7.91)mmHg(1mmHg = 0.133kPa) vs. (7.22±8.01)mmHg和(5.93±9.77)mmHg,P<0.05]。(3)rs216008 C/C基因型(野生型)患者的收缩压降低幅度比rs216008 C/T基因型(突变型)患者更显著[(20.60±12.35)mmHg vs. (13.62±10.21)mmHg,P<0.05]。(4)rs1051375、rs10848683和rs215976基因型患者的血压降低情况相似。

结论

CACNA1C基因中rs2299661和rs216008野生型的EH患者更有可能是CCB单药治疗的反应者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验